Market Overview:
The global levothyroxine sodium market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The oral segment held a market share of 99% in 2018 and is expected to dominate the market throughout the forecast period. The hospitals segment accounted for the majority of the share in 2018 and is projected to grow at a CAGR of 6.1%.
Product Definition:
A synthetic thyroid hormone prescribed to treat hypothyroidism, a condition in which the thyroid gland does not produce enough thyroid hormone. Levothyroxine sodium is also used to prevent and treat goiter, an enlarged thyroid gland.
Oral:
Oral Levothyroxine Sodium is a drug that is used to treat hypothyroidism. It works by replacing the normal function of thyroid hormones in the body. The normal function of thyroid hormones is to control the rate at which cells grow and divide, and also helps with energy production within the cells. An increase in cell growth can lead to cancer, so this drug decreases cell growth by acting on certain brain receptors (neuroendocrine).
Injection:
Injection is a medicine used for the treatment of hypothyroidism. It contains levothyroxine sodium which is an iodine-based hormone replacement drug. Iodide (I2) and Thyroglobulin are the two major raw materials used in its production. The other raw materials include dextrose, starch, and water for injection purposes.
Application Insights:
The others application segment includes clinics, hospitals and other medical facilities. In 2018, this segment had a share of 37% in the global levothyroxine sodium market. The growth of this application is attributed to increasing awareness about treatment options among individuals who cannot access conventional pharmacies due to remote locations or because they are located in areas with limited accessibility. This also contributes towards the growing importance of medication as an essential component for living a healthy life among people from underdeveloped regions across the globe.
In addition, Levothyroxine Sodium is used for treating hypothyroidism which occurs when thyroid hormones are insufficient due to any reason such as illness or surgery affecting the gland that produces these hormones known as thyroid gland.
Regional Analysis:
North America dominated the global market in 2018. The presence of key players, advanced healthcare infrastructure and high patient awareness levels are some of the factors responsible for its large share. In addition, increasing R&D activities to develop new formulations is expected to drive growth during the forecast period. Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income levels and improving healthcare facilities in emerging countries such as China and India.
Growth Factors:
- Increasing prevalence of thyroid disorders: The global prevalence of thyroid disorders is increasing at a rapid pace. This is primarily attributed to the changing lifestyle and dietary habits. Levothyroxine Sodium is the most commonly prescribed drug for treating thyroid disorders and its demand is expected to rise in the coming years.
- Growing awareness about thyroid diseases: There is a growing awareness among people about different types of thyroid diseases and their symptoms. This has led to an increase in the number of people who are seeking treatment for these conditions, thereby driving the growth of Levothyroxine Sodium market.
- Rising incidence of obesity: Obesity has emerged as one of the leading risk factors for developing various types of thyroid diseases such as hypothyroidism, hyperthyroidism, etc., Consequently, there has been a significant rise in demand for Levothyroxine Sodium drugs from obese patients in recent years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Levothyroxine Sodium Market Research Report
By Type
Oral, Injection, Oral had a market share of 99% in 2018.
By Application
Hospitals, Pharmacy, Others, Pharmacy is the greatest segment of Levothyroxine Sodium application, with a share of 63% in 2018.
By Companies
Abbvie, Mylan Pharma, Merck, Pfizer, Lannett Company, Novartis, Fresenius Kabi, IBSA, Piramal Critical Care, Abbott
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Levothyroxine Sodium Market Report Segments:
The global Levothyroxine Sodium market is segmented on the basis of:
Types
Oral, Injection, Oral had a market share of 99% in 2018.
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Pharmacy, Others, Pharmacy is the greatest segment of Levothyroxine Sodium application, with a share of 63% in 2018.
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbvie
- Mylan Pharma
- Merck
- Pfizer
- Lannett Company
- Novartis
- Fresenius Kabi
- IBSA
- Piramal Critical Care
- Abbott
Highlights of The Levothyroxine Sodium Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Injection
- Oral had a market share of 99% in 2018.
- By Application:
- Hospitals
- Pharmacy
- Others
- Pharmacy is the greatest segment of Levothyroxine Sodium application, with a share of 63% in 2018.
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Levothyroxine Sodium Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Levothyroxine sodium is a medication used to treat thyroid problems. It is a type of levothyroxine, which is a hormone that helps the body use energy. Levothyroxine sodium comes in tablet form and should be taken with food.
Some of the major players in the levothyroxine sodium market are Abbvie, Mylan Pharma, Merck, Pfizer, Lannett Company, Novartis, Fresenius Kabi, IBSA, Piramal Critical Care, Abbott.
The levothyroxine sodium market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Levothyroxine Sodium Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Levothyroxine Sodium Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Levothyroxine Sodium Market - Supply Chain
4.5. Global Levothyroxine Sodium Market Forecast
4.5.1. Levothyroxine Sodium Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Levothyroxine Sodium Market Size (000 Units) and Y-o-Y Growth
4.5.3. Levothyroxine Sodium Market Absolute $ Opportunity
5. Global Levothyroxine Sodium Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Levothyroxine Sodium Market Size and Volume Forecast by Type
5.3.1. Oral
5.3.2. Injection
5.3.3. Oral had a market share of 99% in 2018.
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Levothyroxine Sodium Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Levothyroxine Sodium Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Pharmacy
6.3.3. Others
6.3.4. Pharmacy is the greatest segment of Levothyroxine Sodium application, with a share of 63% in 2018.
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Levothyroxine Sodium Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Levothyroxine Sodium Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Levothyroxine Sodium Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Levothyroxine Sodium Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Levothyroxine Sodium Demand Share Forecast, 2019-2026
9. North America Levothyroxine Sodium Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Levothyroxine Sodium Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Levothyroxine Sodium Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Pharmacy
9.4.3. Others
9.4.4. Pharmacy is the greatest segment of Levothyroxine Sodium application, with a share of 63% in 2018.
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Levothyroxine Sodium Market Size and Volume Forecast by Type
9.7.1. Oral
9.7.2. Injection
9.7.3. Oral had a market share of 99% in 2018.
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Levothyroxine Sodium Demand Share Forecast, 2019-2026
10. Latin America Levothyroxine Sodium Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Levothyroxine Sodium Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Levothyroxine Sodium Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Pharmacy
10.4.3. Others
10.4.4. Pharmacy is the greatest segment of Levothyroxine Sodium application, with a share of 63% in 2018.
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Levothyroxine Sodium Market Size and Volume Forecast by Type
10.7.1. Oral
10.7.2. Injection
10.7.3. Oral had a market share of 99% in 2018.
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Levothyroxine Sodium Demand Share Forecast, 2019-2026
11. Europe Levothyroxine Sodium Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Levothyroxine Sodium Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Levothyroxine Sodium Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Pharmacy
11.4.3. Others
11.4.4. Pharmacy is the greatest segment of Levothyroxine Sodium application, with a share of 63% in 2018.
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Levothyroxine Sodium Market Size and Volume Forecast by Type
11.7.1. Oral
11.7.2. Injection
1.7.3. Oral had a market share of 99% in 2018.
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Levothyroxine Sodium Demand Share, 2019-2026
12. Asia Pacific Levothyroxine Sodium Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Levothyroxine Sodium Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Levothyroxine Sodium Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Pharmacy
12.4.3. Others
12.4.4. Pharmacy is the greatest segment of Levothyroxine Sodium application, with a share of 63% in 2018.
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Levothyroxine Sodium Market Size and Volume Forecast by Type
12.7.1. Oral
12.7.2. Injection
12.7.3. Oral had a market share of 99% in 2018.
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Levothyroxine Sodium Demand Share, 2019-2026
13. Middle East & Africa Levothyroxine Sodium Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Levothyroxine Sodium Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Levothyroxine Sodium Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Pharmacy
13.4.3. Others
13.4.4. Pharmacy is the greatest segment of Levothyroxine Sodium application, with a share of 63% in 2018.
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Levothyroxine Sodium Market Size and Volume Forecast by Type
13.7.1. Oral
13.7.2. Injection
13.7.3. Oral had a market share of 99% in 2018.
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Levothyroxine Sodium Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Levothyroxine Sodium Market: Market Share Analysis
14.2. Levothyroxine Sodium Distributors and Customers
14.3. Levothyroxine Sodium Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Abbvie
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Mylan Pharma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Merck
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Lannett Company
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Novartis
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Fresenius Kabi
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. IBSA
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Piramal Critical Care
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Abbott
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
